Background

Migraines are a painful and disruptive neurological condition that affects over 40 million Americans. While most treatments rely on taking a daily pill or getting an injection, researchers have developed a prescription digital therapeutic (a medical smartphone app) called CT-132. The app delivers Cognitive Behavioral Therapy (CBT) techniques—like mindfulness, progressive muscle relaxation, and deep lessons—designed to calm the brain’s overactive pain and stress signals. This study combined data from two clinical trials to see if using this 12-week app for preventing migraine attacks alongside a patient’s normal prescription medication could help prevent migraines from happening in the first place.

How the Study Was Done

Researchers combined data from two virtual, decentralized clinical trials involving 678 adult patients who suffer from occasional migraines (defined as 4 to 14 migraine days a month).

• The First Group (ReMMi-D): Included 568 patients who were taking general, non-specific prescription migraine medications.
• The Second Group (ReMMiD-C): Included 110 patients who were already taking modern, advanced migraine prevention drugs known as CGRP inhibitors.
• The Method: Patients were split 1:1 into two groups. Both groups stayed on their normal medications. One group used the real CT-132 app for 5 to 20 minutes a day. The other group used a “sham” (fake) control app that looked identical and had them track their headaches, but didn’t include the actual therapeutic lessons.

Study Results

The combined data from the 12-week trial showed that the real app provided a major advantage over just taking medication alone:

• Fewer Migraine Days: Patients using the real app saw their monthly migraine days drop by an average of 2.84 days, compared to a drop of only 1.98 days in the fake app group.
• Less Disability & Better Quality of Life: Patients using the app reported a significant drop in how much migraines disrupted their lives. Their disability ratings dropped from “very severe” down to a lower, more manageable tier. Furthermore, 82% of the app users stated their overall condition was visibly improved.
• High App Engagement: Patients genuinely stuck with the program. Users completed an average of 90.4% of their daily app tasks and opened the app about 4.4 times a day.
• Perfect Safety Profile: Because the treatment is entirely software-based, there were zero drug-like side effects (such as constipation or injection site pain) and zero app-related safety issues.

Conclusion

The CT-132 app is a safe, reliable, and effective digital tool to help prevent migraines when used alongside standard medical treatments. Whether a patient is on basic prescriptions or advanced, modern migraine medications, this app provides an extra layer of defense to reduce headache days and improve daily life without adding any medical side effects or risks.